Avalon GloboCare Regains Compliance with Nasdaq Stockholders’ Equity Requirement, Launches Marketing for Automated Generative AI Video Platform
Rhea-AI Summary
Avalon GloboCare (NASDAQ: ALBT) announced it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement under Rule 5550(b) and is now in compliance with all continued listing standards. The previously scheduled Nasdaq Hearings Panel session was cancelled and Avalon’s common stock will remain listed and traded on Nasdaq.
The company said restoring compliance supports its ability to pursue growth initiatives, including launching marketing for a generative AI video platform and expanding precision diagnostics and strategic assets.
Positive
- Regained compliance with Nasdaq Rule 5550(b) minimum stockholders' equity
- Nasdaq confirmed compliance with all continued listing standards
- Previously scheduled Nasdaq hearing was cancelled
- Announced launch of marketing for a generative AI video platform
Negative
- Company previously faced a scheduled Nasdaq Hearings Panel session due to noncompliance
News Market Reaction
On the day this news was published, ALBT declined 10.24%, reflecting a significant negative market reaction. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $577K from the company's valuation, bringing the market cap to $5M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Pre-news, ALBT was modestly higher while peers showed mixed moves: LRHC down ~12–20%, WETH up 5.79–7.95%, and OMH up 4.95%. With peers both rising and falling and no same-day peer headlines, the compliance news appears stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | AI platform highlight | Positive | -6.0% | Board director interview promoting RPM’s Catch-Up generative AI video SaaS platform. |
| Dec 15 | AI acquisition deal | Positive | -24.6% | All-stock acquisition of RPM Interactive to bolster AI video capabilities and equity. |
| Dec 01 | KetoAir progress | Positive | -8.1% | Q3 2025 update on KetoAir, UK launch, and Nevada first-responder health program. |
| Aug 28 | UK product launch | Positive | +2.9% | Announcement of KetoAir online sales launch in the UK from September 1, 2025. |
| Jul 28 | Distribution agreement | Positive | +30.8% | Distribution agreement with Saga Health to deploy KetoAir for first responders. |
Recent positive operational and AI announcements have often seen mixed or negative next-day moves, with only some product news producing strong gains.
Over the past six months, Avalon reported several developments around KetoAir™ and its AI strategy. On Jul 28, a distribution deal for KetoAir targeting first responders coincided with a 30.84% gain. Subsequent UK launch and program updates in Aug–Dec 2025 produced smaller or negative moves. The Dec 15 RPM Interactive acquisition, which was linked to lifting equity above Nasdaq’s $2.5M minimum, saw a -24.63% reaction. Today’s Nasdaq compliance confirmation connects directly to that equity-improvement path.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite the favorable Nasdaq compliance news would fit prior patterns where positive AI and product developments sometimes led to selling, such as the RPM acquisition reaction of -24.63%. In that context, investors might have focused on past operating losses and financing structures rather than the listing relief. Any sustained weakness would hinge on confidence in monetizing the generative AI video platform and broader precision diagnostics initiatives.
Key Terms
nasdaq capital market regulatory
nasdaq listing rule 5550(b) regulatory
continued listing standards regulatory
generative ai technical
AI-generated analysis. Not financial advice.
FREEHOLD, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy and generative AI publishing and software, today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b). Nasdaq further confirmed that the Company is now in compliance with all applicable continued listing standards.
As a result, the previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and the Company’s common stock will continue to be listed and traded on the Nasdaq Capital Market.
“We are pleased to have regained compliance with Nasdaq’s minimum stockholders’ equity requirement, reflecting the progress we have made in strengthening our financial position and our continued focus on long-term shareholder value,” said Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. “With full Nasdaq compliance restored, we believe we are well positioned to execute on our growth initiatives, including launching marketing for our generative AI video platform, as well as expansion across precision diagnostics and strategic assets.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy, and generative artificial intelligence publishing and software through its Avalon Quantum AI, LLC subsidiary. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAirTM is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate.
For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).
Additional Information About the Proposed Merger for Investors and Shareholders
This communication relates to the proposed merger (the “proposed Merger”) of Avalon and YOOV Group Holding Limited (“YOOV”). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4, as amended, that contains a preliminary prospectus and preliminary proxy statement of Avalon (the “proxy statement/prospectus”). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon’s stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.
Participants in the Solicitation
Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon’s directors and executive officers is available in Avalon’s Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What did Avalon GloboCare (ALBT) announce on January 12, 2026 about Nasdaq compliance?
Will Avalon GloboCare (ALBT) remain listed on Nasdaq after the January 12, 2026 update?
What growth initiative did Avalon GloboCare (ALBT) say it will pursue after regaining Nasdaq compliance?
Does the January 12, 2026 announcement from Avalon GloboCare (ALBT) include financial results or figures?
Why was a Nasdaq Hearings Panel session previously scheduled for Avalon GloboCare (ALBT)?
Who commented for Avalon GloboCare (ALBT) on the Nasdaq compliance update on January 12, 2026?
